This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion

Updated from 2:21 p.m. EDT

Shares of Quidel (QDEL) rose 7.3% after the board authorized the repurchase of up to $25 million in common stock. The provider of point-of-care rapid diagnostic tests said that shares may be purchased in both the open market and privately negotiated transactions for up to two years. Quidel has 32 million common shares outstanding. The stock closed up 34 cents to $5.01.

Angeion (ANGN) fell 5.4% after posting a narrower second-quarter loss. The medical diagnostic systems maker reported a loss of $238,000, or 7 cents a share, for the quarter ended April 30, vs. a loss of $879,000, or 24 cents a share, a year ago. Revenue rose 22% from a year earlier to $6 million. "Also noteworthy is the acceptance we're receiving from our Asian, European and South American markets where we've launched market specific products to meet international performance and pricing requirements," said CEO Rodney Young. The stock closed down 15 cents to $2.65.

Eli Lilly (LLY) and Alkermes (ALKS) rose after saying a phase II clinical study showed that people with type 1 diabetes who used their inhaled insulin system achieved similar blood sugar levels to patients who used injected insulin. Also, the companies said 80% of the patients preferred the inhaler system at mealtime over injected insulin. "These studies, taken together, show that inhaled insulin delivered by the Lilly/Alkermes system is equivalent in various clinical measures to injected insulin," said Dr. Douglas Muchmore, medical fellow at Lilly. The companies expect to begin enrolling patients in additional clinical studies in July. Eli Lilly closed up 35 cents to $57.65, while Alkermes finished up 69 cents, or 5.6%, to $12.94.

Isis Pharmaceuticals (ISIS) announced that its second-generation antisense drug ISIS 113715 reduced HbA1C and plasma glucose in diabetic patients after six weeks of dosing in a phase II study. "ISIS 113715 produced these promising results at low weekly doses and without the major side effects associated with other antidiabetic therapies, such as hypoglycemia, metabolic acidosis, nausea or weight gain," said Mark Wedel, chief medical officer at Isis. HbA1C reflects the average blood glucose level over a three-to-four-month period and is the standard measure used by physicians to tell if a patient's blood sugar is under control. The stock finished down a penny $3.89.

Other health stocks on the move are Merck (MRK), up 23 cents to $31.78; Pfizer (PFE), up 50 cents to $28.39; Elan (ELN), down 6 cents to $6.72; Abbott Labs (ABT), up 17cents to $49.02; and Johnson & Johnson (JNJ), up 11 cents to $66.58.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs